<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695617</url>
  </required_header>
  <id_info>
    <org_study_id>ML4960</org_study_id>
    <nct_id>NCT00695617</nct_id>
  </id_info>
  <brief_title>Citrate Anticoagulation During MARS Treatment</brief_title>
  <official_title>Citrate Anticoagulation During MARS Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal anticoagulation procedure during MARS treatment has not been defined. In various
      multi-centre trials, such as MARS-RELIEF, anticoagulation procedures are left to the
      discretion of the treating physician. On the one hand, given the increased risk of bleeding
      associated with liver failure, high dosage of anticoagulation therapy should be avoided. On
      the other hand, contact of blood or blood components with the extracorporeal circuit will
      likely result in coagulation activation or even loss of coagulation factors.

      Citrate anticoagulation has gained popularity, especially in hemodialysis patients. It
      results in a highly effective anticoagulation, exclusively confined to the extracorporeal
      circulation. Moreover, dependent on the type of dialyser membrane, citrate anticoagulation
      resulted in reduced activation of other cellular components.

      In contrast to hemodialysis patients, experience with citrate anticoagulation during
      treatment with artificial liver devices is limited. The liver contributes substantially to
      the metabolism of exogenous citrate. As a result, cirrhotic patients have decreased
      endogenous citrate clearances. Importantly, blood purification devices contribute
      substantially to overall citrate clearance, thereby preventing accumulation of citrate.
      Several centres, including our own, have gained experience with citrate anticoagulation
      during fractionated plasma separation and adsorption (FPSA), a related liver dialysis device,
      in the treatment of liver failure patients.

      Citrate anticoagulation during MARS treatment has not been studied so far.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extracorporeal circuit coagulation events</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Citrate tolerability</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>citrate first</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>no anticoagulation first</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trisodiumcitrate</intervention_name>
    <description>trisodiumcitrate 1.035 M</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trisodiumcitrate</intervention_name>
    <description>trisodiumcitrate 1.035 M</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled MARS treatment

          -  Age over 18 years

          -  Informed consent

          -  Admitted to Intensive Care Unit

        Exclusion Criteria:

          -  Blood or plasma transfusion within 48 hours before study

          -  Hypocalcemia (ionised Ca &lt; 0.90 mmol/l)

          -  Acidosis (pH &lt; 7.25) due to any cause

          -  Use of citrate containing medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Evenepoel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjorn Meijers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Wilmer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Nevens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter Evenepoel, MD, PhD</last_name>
    <phone>+32 16 344580</phone>
    <email>pieter.evenepoel@uz.kuleuven.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjorn Meijers, MD</last_name>
    <phone>+32 16 342352</phone>
    <email>bjorn.meijers@uz.kuleuven.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bj√∂rn Meijers, MD</last_name>
      <phone>+32 16 342352</phone>
      <email>bjorn.meijers@uz.kuleuven.ac.be</email>
    </contact>
    <investigator>
      <last_name>Bjorn Meijers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pieter Evenepoel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Meijers BK, Verhamme P, Nevens F, Hoylaerts MF, Bammens B, Wilmer A, Arnout J, Vanrenterghem Y, Evenepoel P. Major coagulation disturbances during fractionated plasma separation and adsorption. Am J Transplant. 2007 Sep;7(9):2195-9. Epub 2007 Jul 19.</citation>
    <PMID>17640311</PMID>
  </reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>June 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2008</study_first_posted>
  <last_update_submitted>March 4, 2009</last_update_submitted>
  <last_update_submitted_qc>March 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pieter Evenepoel</name_title>
    <organization>University Hospitals Leuven</organization>
  </responsible_party>
  <keyword>MARS treatment</keyword>
  <keyword>Citrate anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 14, 2011</submitted>
    <returned>October 21, 2011</returned>
    <submitted>May 2, 2017</submitted>
    <returned>September 29, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

